Parkwalk Advisors

Echopoint Medical Ltd, established in 2018 and headquartered in London, specializes in developing medical devices that incorporate optical-fibre based sensors. The company leverages optical fibre sensing technologies to enhance precision and efficacy in invasive cardiology and other minimally invasive procedures, with a focus on transforming the diagnosis and treatment of cardiovascular diseases.

Nu Quantum is a Cambridge-based quantum technology company developing the networking infrastructure required to scale quantum computers. It produces quantum photonics hardware, including photon sources and detectors, and nano-engineered materials for quantum light generation and ultra-sensitive detection. The firm is building a complete hardware system to create entangled qubit networks by interconnecting computing cores into large distributed clusters, featuring a high-speed network interface, photonic switching fabric, and control systems. This entangled fabric enables secure exchange of cryptographic keys and underpins quantum encryption links for sensitive communications. Partnerships with leading quantum companies, governments, and research groups support the path to market.

PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that specializes in the design of small molecule drugs through the integration of medicinal chemistry and artificial intelligence computational methods. Established in 2016, the company has created a rapid and cost-effective approach to identify superior chemical starting points, thereby facilitating the discovery of essential new medicines.

AccelerComm is a semiconductor IP-core company that provides forward error correction and channel coding solutions for wireless communications. It develops hardware-friendly encoders and decoders, including 3GPP-compliant encoding/decoding chains, turbo decoders, LDPC chains, and polar encoder/decoder facilities, to accelerate next-generation wireless systems and overcome bottlenecks in error correction decoding caused by noise and interference. The company focuses on patent-pending channel coding technology that enhances data throughput and efficiency for 3GPP-based networks and related applications, including base stations and mobile devices. Headquartered in Southampton, United Kingdom, AccelerComm aims to enable cost-effective, high-performance digital communications across multiple standards.

Symetrica Ltd. is a company that specializes in the development and commercialization of integrated radiation detection and identification technologies. Founded in 2002 and headquartered in Southampton, United Kingdom, with an additional office in Maynard, Massachusetts, Symetrica serves various sectors including military, homeland security, medical diagnostics, geophysical, and space research. The company produces a range of advanced devices, such as handheld and backpack-mounted sensors, vehicle-based detectors, and drive-through scanners, which utilize machine learning to enhance operational effectiveness for security teams. These systems are employed by customs and border protection, law enforcement, military, and emergency services around the world, enabling them to identify threats and respond efficiently.

Crypto Quantique develops quantum-driven security solutions for connected devices by designing a secure chip on silicon that uses quantum processes to generate cryptographic keys. The chip can be integrated into new devices or retrofitted into existing ones, enabling multiple applications to operate with unique, unforgeable keys that do not need to be stored. The company combines cryptography and quantum physics in a platform that delivers hardware and software products for future-proof cybersecurity, with a focus on protecting local networks and IoT environments through end-to-end security in a scalable manner. Founded in 2015 and based in London, Crypto Quantique aims to provide robust protection for the Internet of Things by enabling on-demand cryptographic operations and key management.

Concr is a mission-driven techbio company that uses established methods from astrophysics to predict patient outcomes and treatment response to cancer therapies. The approach enables iterative learning from fragmented data across the drug development and clinical journey, producing accurate multi-modal tumor models without relying on large, homogeneous datasets. Its cloud-native platform FarrSight supports computational simulation of clinical trials, prediction of therapeutic response and biomarkers, and standard bioinformatics analyses. Headquartered in London with a wholly owned subsidiary in Brisbane, Concr provides a cloud-based system that identifies optimal treatments for individuals, reduces resistance, and offers patient-specific progression insights and evidence-based treatment plans to guide proactive therapy.

GripAble Ltd. is a London-based company founded in 2017 that specializes in the development of digital therapy devices aimed at improving rehabilitation for individuals with movement impairments. The company’s flagship product, the GripAble Digital Handgrip, is a sensitive, portable device that wirelessly connects to a mobile application. This app allows users to engage in interactive therapy games designed to facilitate the assessment and training of hand and arm functions. GripAble's solutions target patients suffering from conditions such as stroke, arthritis, cerebral palsy, and trauma, addressing the challenges faced by over 500 million people globally who experience impaired arm mobility. By combining hardware with gamified therapy, GripAble enhances patient engagement and enables effective self-training both in clinical settings and at home.

BibliU operates a digital platform that provides colleges and universities with managed access to millions of textbooks and academic resources. It offers automation tools, analytics, and offline support, enhancing student learning efficiency.

Founded in London in 2016, Bramble Energy specializes in designing and manufacturing high-performance, low-cost fuel cell stacks using printed circuit board (PCB) technology. Their products cater to stationary, portable, and automotive sectors, with customizable options available.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

PetMedix Ltd is a veterinary biopharmaceutical company based in Hinxton, United Kingdom, that specializes in therapeutic drug discovery for pets. Founded in 2017, the company utilizes advanced scientific techniques to develop innovative antibody therapies aimed at improving the health and well-being of companion animals. PetMedix has created specialized platforms, including the Ky9 and Felyne transgenic mouse systems, which are designed to produce therapeutic-quality antibodies tailored for pets. This approach allows for the generation of a diverse repertoire of antibodies that mirrors the immune systems of companion animals, enabling veterinarians to administer safe and effective monoclonal antibody treatments. By applying over thirty years of expertise in human drug development to veterinary medicine, PetMedix is dedicated to enhancing the quality of life for pets through cutting-edge therapies.

Bonnet Ltd. is a London-based company established in 2019 that specializes in charging-as-a-service solutions for electric vehicle drivers. Its platform simplifies the charging experience by enabling users to access a wide network of public chargers through a single application, eliminating the need for separate registrations with individual charging networks. By streamlining the process, Bonnet aims to enhance convenience for both drivers and businesses, facilitating easier and more efficient electric vehicle charging.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.

GripAble Ltd. is a London-based company founded in 2017 that specializes in the development of digital therapy devices aimed at improving rehabilitation for individuals with movement impairments. The company’s flagship product, the GripAble Digital Handgrip, is a sensitive, portable device that wirelessly connects to a mobile application. This app allows users to engage in interactive therapy games designed to facilitate the assessment and training of hand and arm functions. GripAble's solutions target patients suffering from conditions such as stroke, arthritis, cerebral palsy, and trauma, addressing the challenges faced by over 500 million people globally who experience impaired arm mobility. By combining hardware with gamified therapy, GripAble enhances patient engagement and enables effective self-training both in clinical settings and at home.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

Nu Quantum is a Cambridge-based quantum technology company developing the networking infrastructure required to scale quantum computers. It produces quantum photonics hardware, including photon sources and detectors, and nano-engineered materials for quantum light generation and ultra-sensitive detection. The firm is building a complete hardware system to create entangled qubit networks by interconnecting computing cores into large distributed clusters, featuring a high-speed network interface, photonic switching fabric, and control systems. This entangled fabric enables secure exchange of cryptographic keys and underpins quantum encryption links for sensitive communications. Partnerships with leading quantum companies, governments, and research groups support the path to market.

Founded in London in 2016, Bramble Energy specializes in designing and manufacturing high-performance, low-cost fuel cell stacks using printed circuit board (PCB) technology. Their products cater to stationary, portable, and automotive sectors, with customizable options available.

Symetrica Ltd. is a company that specializes in the development and commercialization of integrated radiation detection and identification technologies. Founded in 2002 and headquartered in Southampton, United Kingdom, with an additional office in Maynard, Massachusetts, Symetrica serves various sectors including military, homeland security, medical diagnostics, geophysical, and space research. The company produces a range of advanced devices, such as handheld and backpack-mounted sensors, vehicle-based detectors, and drive-through scanners, which utilize machine learning to enhance operational effectiveness for security teams. These systems are employed by customs and border protection, law enforcement, military, and emergency services around the world, enabling them to identify threats and respond efficiently.

Founded in London in 2016, Bramble Energy specializes in designing and manufacturing high-performance, low-cost fuel cell stacks using printed circuit board (PCB) technology. Their products cater to stationary, portable, and automotive sectors, with customizable options available.

Symetrica Ltd. is a company that specializes in the development and commercialization of integrated radiation detection and identification technologies. Founded in 2002 and headquartered in Southampton, United Kingdom, with an additional office in Maynard, Massachusetts, Symetrica serves various sectors including military, homeland security, medical diagnostics, geophysical, and space research. The company produces a range of advanced devices, such as handheld and backpack-mounted sensors, vehicle-based detectors, and drive-through scanners, which utilize machine learning to enhance operational effectiveness for security teams. These systems are employed by customs and border protection, law enforcement, military, and emergency services around the world, enabling them to identify threats and respond efficiently.

PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that specializes in the design of small molecule drugs through the integration of medicinal chemistry and artificial intelligence computational methods. Established in 2016, the company has created a rapid and cost-effective approach to identify superior chemical starting points, thereby facilitating the discovery of essential new medicines.

Covatic develops broadcast personalization software and a consumer insights platform that enables on-device personalization for applications. Incorporated in 2016, the company is based in Birmingham, United Kingdom, with an additional office in London. Its platform provides an on-device software development kit that leverages trusted first-party and offline consented data to create contextual audience segments, helping media companies deliver relevant advertising while strengthening user trust and complying with privacy regulations.

Echopoint Medical Ltd, established in 2018 and headquartered in London, specializes in developing medical devices that incorporate optical-fibre based sensors. The company leverages optical fibre sensing technologies to enhance precision and efficacy in invasive cardiology and other minimally invasive procedures, with a focus on transforming the diagnosis and treatment of cardiovascular diseases.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.

Symetrica Ltd. is a company that specializes in the development and commercialization of integrated radiation detection and identification technologies. Founded in 2002 and headquartered in Southampton, United Kingdom, with an additional office in Maynard, Massachusetts, Symetrica serves various sectors including military, homeland security, medical diagnostics, geophysical, and space research. The company produces a range of advanced devices, such as handheld and backpack-mounted sensors, vehicle-based detectors, and drive-through scanners, which utilize machine learning to enhance operational effectiveness for security teams. These systems are employed by customs and border protection, law enforcement, military, and emergency services around the world, enabling them to identify threats and respond efficiently.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

Cytora provides a configurable risk digitization and analytics platform for commercial insurance. The platform digitizes each incoming risk, augments it with internal and external data sources, and evaluates it against rules governing appetite and priority before routing to downstream underwriting systems for automated or manual processing. Using artificial intelligence, Cytora learns patterns of risk and loss outcomes over time, computes a risk rank, score, and price for each property and organization, and helps insurers target profitable risks, improve risk selection, and optimize pricing. The company was founded in 2014 and is headquartered in London.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

PetMedix Ltd is a veterinary biopharmaceutical company based in Hinxton, United Kingdom, that specializes in therapeutic drug discovery for pets. Founded in 2017, the company utilizes advanced scientific techniques to develop innovative antibody therapies aimed at improving the health and well-being of companion animals. PetMedix has created specialized platforms, including the Ky9 and Felyne transgenic mouse systems, which are designed to produce therapeutic-quality antibodies tailored for pets. This approach allows for the generation of a diverse repertoire of antibodies that mirrors the immune systems of companion animals, enabling veterinarians to administer safe and effective monoclonal antibody treatments. By applying over thirty years of expertise in human drug development to veterinary medicine, PetMedix is dedicated to enhancing the quality of life for pets through cutting-edge therapies.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

Founded in London in 2016, Bramble Energy specializes in designing and manufacturing high-performance, low-cost fuel cell stacks using printed circuit board (PCB) technology. Their products cater to stationary, portable, and automotive sectors, with customizable options available.

OxSyBio Ltd. is a biotechnology company based in London, United Kingdom, specializing in the development of advanced 3D printing techniques for creating tissue-like and functional tissues intended for medical research and clinical applications. Founded in 2014, the company focuses on innovative methods that utilize three-dimensional networks of lipid monolayer aqueous droplets, which can conduct electrical signals along designated pathways and self-fold into intricate structures. These engineered tissues aim to facilitate organ repair or replacement, supporting precision medicine initiatives. The technology builds upon pioneering research from Professor Hagan Bayley's group at the University of Oxford, emphasizing the integration of chemical and synthetic biology in the field of regenerative medicine.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

Cytora provides a configurable risk digitization and analytics platform for commercial insurance. The platform digitizes each incoming risk, augments it with internal and external data sources, and evaluates it against rules governing appetite and priority before routing to downstream underwriting systems for automated or manual processing. Using artificial intelligence, Cytora learns patterns of risk and loss outcomes over time, computes a risk rank, score, and price for each property and organization, and helps insurers target profitable risks, improve risk selection, and optimize pricing. The company was founded in 2014 and is headquartered in London.

Ionix Advanced Technologies designs and manufactures high-temperature piezoelectric devices and materials, offering sensors, actuators and transducers based on novel high-temperature piezoelectric materials and anisotropic ceramics to reduce ultrasonic crosstalk and improve acoustic transmission. It serves industrial processes in aerospace, oil and gas, nuclear power, automotive, and ultrasound and nondestructive testing markets, focusing on high-performance systems that operate reliably in extreme environments, including high temperatures and radiation. The company enables continuous monitoring and safer, more efficient operation of equipment. Founded in 2011 and based in Leeds, United Kingdom.

Creavo Medical Technologies Ltd. is a UK-based medical device company focused on developing innovative imaging technologies for acute medical settings. Incorporated in 2014, the company has its headquarters in Coventry and additional facilities in Leeds. Creavo specializes in creating portable, battery-powered devices that utilize magnetocardiography to detect heart-related issues, such as acute coronary syndromes and ischemia, directly at the patient's bedside. Founded by a team of clinical, research, and business experts, the company aims to improve diagnostic techniques and enhance patient outcomes in healthcare settings. Creavo Medical Technologies was previously known as Quantum Imaging Limited before rebranding in September 2016.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

BibliU operates a digital platform that provides colleges and universities with managed access to millions of textbooks and academic resources. It offers automation tools, analytics, and offline support, enhancing student learning efficiency.

Covatic develops broadcast personalization software and a consumer insights platform that enables on-device personalization for applications. Incorporated in 2016, the company is based in Birmingham, United Kingdom, with an additional office in London. Its platform provides an on-device software development kit that leverages trusted first-party and offline consented data to create contextual audience segments, helping media companies deliver relevant advertising while strengthening user trust and complying with privacy regulations.

Cytora provides a configurable risk digitization and analytics platform for commercial insurance. The platform digitizes each incoming risk, augments it with internal and external data sources, and evaluates it against rules governing appetite and priority before routing to downstream underwriting systems for automated or manual processing. Using artificial intelligence, Cytora learns patterns of risk and loss outcomes over time, computes a risk rank, score, and price for each property and organization, and helps insurers target profitable risks, improve risk selection, and optimize pricing. The company was founded in 2014 and is headquartered in London.

Fluidic Analytics Limited, founded in 2013 as a spin-out from the University of Cambridge, specializes in the design, development, and manufacturing of advanced analytical tools for protein characterization. The company focuses on creating innovative products that facilitate in-solution sizing and quantification of proteins, with offerings such as Fluidity One and Fluidity One-W, which enable high sensitivity analysis of protein size and interaction kinetics. These tools are essential for a variety of applications, including assessing protein quality, interactions, and aggregation. Fluidic Analytics serves a diverse clientele, including scientists, clinics, and healthcare providers, aiming to enhance the understanding of protein behavior and its implications in biological processes. By combining cutting-edge technology with a commitment to accessibility and user data ownership, the company aspires to transform the field of protein science, paralleling the revolutionary impact of advancements in DNA sequencing.

Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Healthera's technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools and data science environments, empowering users to unlock insights from diverse IoT data sources, from real-time fleet tracking to local service applications.

Cytora provides a configurable risk digitization and analytics platform for commercial insurance. The platform digitizes each incoming risk, augments it with internal and external data sources, and evaluates it against rules governing appetite and priority before routing to downstream underwriting systems for automated or manual processing. Using artificial intelligence, Cytora learns patterns of risk and loss outcomes over time, computes a risk rank, score, and price for each property and organization, and helps insurers target profitable risks, improve risk selection, and optimize pricing. The company was founded in 2014 and is headquartered in London.

Ionix Advanced Technologies designs and manufactures high-temperature piezoelectric devices and materials, offering sensors, actuators and transducers based on novel high-temperature piezoelectric materials and anisotropic ceramics to reduce ultrasonic crosstalk and improve acoustic transmission. It serves industrial processes in aerospace, oil and gas, nuclear power, automotive, and ultrasound and nondestructive testing markets, focusing on high-performance systems that operate reliably in extreme environments, including high temperatures and radiation. The company enables continuous monitoring and safer, more efficient operation of equipment. Founded in 2011 and based in Leeds, United Kingdom.

Orthox Ltd. is a medical implant company based in Abingdon, United Kingdom, that specializes in developing tissue regenerative implants for knee cartilage injuries. Founded to commercialize technology from Oxford University, Orthox aims to transform the treatment of cartilage damage, addressing the needs of over 300 million patients worldwide affected by osteoarthritis. The company's flagship product, FibroFix, is a hydrogel implant designed to emulate human knee cartilage, enabling effective repair and regeneration of damaged tissues. Orthox offers several variations of FibroFix, including FibroFix Meniscus for meniscal cartilage repair and FibroFix Cartilage for articular cartilage damage. The implants promote integration with the body's cells, facilitating a return to active, pain-free living. With plans to expand its technology to other joints and additional applications beyond orthopaedics, Orthox is positioned to capitalize on the rapidly growing biomaterials market, projected to exceed $250 billion by 2025.

Fluidic Analytics Limited, founded in 2013 as a spin-out from the University of Cambridge, specializes in the design, development, and manufacturing of advanced analytical tools for protein characterization. The company focuses on creating innovative products that facilitate in-solution sizing and quantification of proteins, with offerings such as Fluidity One and Fluidity One-W, which enable high sensitivity analysis of protein size and interaction kinetics. These tools are essential for a variety of applications, including assessing protein quality, interactions, and aggregation. Fluidic Analytics serves a diverse clientele, including scientists, clinics, and healthcare providers, aiming to enhance the understanding of protein behavior and its implications in biological processes. By combining cutting-edge technology with a commitment to accessibility and user data ownership, the company aspires to transform the field of protein science, paralleling the revolutionary impact of advancements in DNA sequencing.

First Light Fusion Limited is a UK-based company that specializes in researching advanced implosion processes aimed at electricity generation through inertial confinement fusion. Founded in 2011 as a spin-out from the University of Oxford, the company focuses on harnessing fundamental physics to explore various innovative energy generation methods. It employs a team of engineers and physicists who engage in theoretical analysis, detailed numerical simulations, and experimental validation to develop new energy sources. First Light Fusion collaborates closely with several academic institutions, including the University of Oxford, Warwick University, University College London, and Imperial College London. The company, originally named Oxyntix Ltd., rebranded in June 2014 to reflect its focus on fusion energy research.

Symetrica Ltd. is a company that specializes in the development and commercialization of integrated radiation detection and identification technologies. Founded in 2002 and headquartered in Southampton, United Kingdom, with an additional office in Maynard, Massachusetts, Symetrica serves various sectors including military, homeland security, medical diagnostics, geophysical, and space research. The company produces a range of advanced devices, such as handheld and backpack-mounted sensors, vehicle-based detectors, and drive-through scanners, which utilize machine learning to enhance operational effectiveness for security teams. These systems are employed by customs and border protection, law enforcement, military, and emergency services around the world, enabling them to identify threats and respond efficiently.

First Light Fusion Limited is a UK-based company that specializes in researching advanced implosion processes aimed at electricity generation through inertial confinement fusion. Founded in 2011 as a spin-out from the University of Oxford, the company focuses on harnessing fundamental physics to explore various innovative energy generation methods. It employs a team of engineers and physicists who engage in theoretical analysis, detailed numerical simulations, and experimental validation to develop new energy sources. First Light Fusion collaborates closely with several academic institutions, including the University of Oxford, Warwick University, University College London, and Imperial College London. The company, originally named Oxyntix Ltd., rebranded in June 2014 to reflect its focus on fusion energy research.